Home Clinical Topics FDA approves Votrient for advanced soft tissue sarcoma

FDA approves Votrient for advanced soft tissue sarcoma

On April 26, the U.S. Food and Drug Administration (FDA) approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here